Table 2. Two-Year Outcomes by Receipt of Aflibercept During Follow-up in the Initial Observation Group.
| Outcome | Eyes, No. (%) | |
|---|---|---|
| Did Not Receive Aflibercept (n = 132) | Received Aflibercept (n = 76) | |
| Visual Acuity, Letter Score | ||
| Baselinea | ||
| Mean (SD) | 85.4 (3.5) | 84.8 (4.2) |
| Mean Snellen equivalent | 20/20 | 20/20 |
| Median (IQR) | 85.0 (88.0 to 83.0) | 84.0 (87.0 to 81.0) |
| Median Snellen equivalent (IQR) | 20/20 (20/20 to 20/25) | 20/20 (20/20 to 20/25) |
| 20/20 or better (≥84 letters) | 90 (68) | 43 (57) |
| 2 y | ||
| Mean (SD) | 86.6 (5.2) | 80.0 (14.4) |
| Mean Snellen equivalent | 20/20 | 20/25 |
| Median (IQR) | 87.0 (90.0 to 83.5) | 83.5 (87.0 to 78.5) |
| Median Snellen equivalent (IQR) | 20/20 (20/16 to 20/25) | 20/25 (20/20 to 20/32) |
| 20/20 or better (≥84 letters) | 99 (75) | 38 (50) |
| Change from baseline | ||
| Mean (SD) | 1.2 (4.5) | −3.0 (8.0) |
| Median (IQR) | 1.5 (−1.0 to 5.0) | −2.0 (−6.0 to 1.0) |
| ≥5-Letter decrease | 16 (12) | 23 (30) |
| ≥10-Letter decrease | 3 (2) | 11 (14) |
| ≥15-Letter decrease | 1 (<1) | 7 (9) |
| OCT Central Subfield Thickness (Zeiss-Stratus Equivalent), μm | ||
| Baselinea | ||
| Mean (SD) | 308 (59) | 331 (70) |
| Median (IQR) | 292 (273 to 324) | 312 (289 to 357) |
| 2 yb | ||
| Mean (SD) | 276 (69) | 267 (79) |
| Median (IQR) | 264 (229 to 306) | 250 (218 to 315) |
| Change from baselineb | ||
| Mean (SD) | −30 (66) | −62 (86) |
| Median (IQR) | −33 (−68 to −1) | −53 (−117 to −14) |
| ≥10% Central subfield thickness decrease | 61 (46) | 45 (60) |
| No center-involved diabetic macular edema and ≥10% central subfield thickness decreasec | 41 (31) | 33 (44) |
Abbreviations: CST, central subfield thickness; IQR, interquartile range; OCT, optical coherence tomography.
a
Mean of screening and randomization values.
b
Unavailable for 1 eye that received aflibercept.
c
Defined by OCT machine and sex: Heidelberg Spectralis CST at least 305 μm in women and at least 320 μm in men; Zeiss Cirrus CST at least 290 μm in women and at least 305 μm in men.